Salmen, Natasha L.
Curtis, Deven P.
Baumann, Anthony N.
Willets, Jared
Brodell, Robert T.
Article History
Received: 2 June 2024
Revised: 2 June 2024
Accepted: 15 June 2024
First Online: 5 July 2024
Declarations
:
: The authors declare no competing interests.
: Robert Brodell, M.D. discloses the following potential conflicts of interest: Advisory boards: Novan and Amgen. Research funding: Pfizer, Novartis, and Sanofi. Stock: Veragen, Inc. Natasha Salmen, Deven Curtis, Anthony Baumann, and Jared Willets have no conflicts to disclose.